Rotterdam criteria for polycystic ovary syndrome (PCOS) (also searched with possessive/alternate eponym spelling where applicable, ICD-10: E28.2) is an internationally accepted diagnostic framework established by a consensus workshop sponsored by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) in 20037. It defines polycystic ovary syndrome as a heterogeneous endocrine and metabolic disorder diagnosed by the presence of at least two of the following three core manifestations: (1) oligo- or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, and (3) polycystic ovarian morphology on pelvic ultrasonography, provided that other secondary etiologies are systematically excluded3,7. By broadening the diagnostic scope beyond the older National Institutes of Health criteria—which strictly mandated hyperandrogenism—the Rotterdam criteria capture milder phenotypic presentations, facilitating earlier recognition and intervention for reproductive and metabolic risks3,6,7.
Etiology & Risk Factors
- Genetic and Epigenetic Predisposition: Familial clustering demonstrates strong heritability, with first-degree relatives of affected individuals carrying a significantly increased risk of metabolic and reproductive dysfunction due to polygenic susceptibility loci3.
- Neuroendocrine Abnormalities: Alterations in hypothalamic pulse generator frequency drive an abnormally high frequency of gonadotropin-releasing hormone (GnRH) release, preferentially stimulating luteinizing hormone (LH) synthesis over follicle-stimulating hormone (FSH)7.
- Metabolic and Insulin Resistance Pathways: Peripheral insulin resistance accompanied by compensatory hyperinsulinemia acts synergistically with luteinizing hormone to drive ovarian androgen production while directly suppressing hepatic synthesis of sex hormone-binding globulin (SHBG)3,4.
- Environmental and Lifestyle Factors: Obesity, sedentary lifestyle, and intrauterine exposure to excess androgens or high maternal body mass index exacerbate the phenotypic severity and metabolic complications of the syndrome3,4.
Pathophysiology
The pathophysiology of polycystic ovary syndrome is driven by a complex interplay between neuroendocrine dysregulation, ovarian dysfunction, and metabolic impairment3. At the hypothalamic level, increased pulse frequency of gonadotropin-releasing hormone leads to an elevated LH-to-FSH ratio. This relative deficiency in FSH impairs the selection and maturation of a dominant follicle, resulting in cycle arrest at the small antral follicle stage and subsequent accumulation of multiple subcapsular cysts within the ovarian cortex3,7.
Simultaneously, the hyperinsulinemic state resulting from peripheral insulin resistance enhances ovarian responsiveness to LH. Insulin acts directly on ovarian theca cells to upregulate cytochrome P450c17alpha activity, accelerating androgen biosynthesis (specifically androstenedione and testosterone). Concurrently, elevated insulin and androgen levels suppress hepatic production of sex hormone-binding globulin (SHBG). The reduction in circulating SHBG vastly increases the bioavailable fraction of free testosterone, which binds to peripheral androgen receptors in the skin and hair follicles to cause cutaneous manifestations such as hirsutism and acne. In the endometrium, chronic exposure to uninterrupted estrogen stimulation in the absence of adequate progesterone counter-regulation from regular ovulation creates a milieu predisposing to endometrial hyperplasia and malignant transformation4,7.
Clinical Presentation & Classic Clinical Signs
- History & Cardinal Symptoms: Patients typically present during adolescence or early adulthood with menstrual irregularities, most commonly oligomenorrhea (fewer than nine menstrual cycles per year) or secondary amenorrhea, alongside subfertility or infertility. Cutaneous complaints include progressive hirsutism, moderate-to-severe inflammatory acne, and female pattern hair loss (androgenetic alopecia)3,4.
- Physical Examination & Named Clinical Signs: Examination often reveals a modified Ferriman-Gallwey score exceeding the diagnostic threshold for hirsutism (typically $\ge 4-6$ depending on ethnicity). Cutaneous markers of insulin resistance, such as acanthosis nigricans (velvety hyperpigmented plaques commonly distributed over the nape of the neck, axillae, and inframammary folds), may be observed in insulin-resistant phenotypes7. Weight trajectories frequently demonstrate central or android adiposity distribution.
Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)
| Diagnostic Modality / Test | Expected Clinical & Radiological / Laboratory Finding |
|---|---|
| Gold-Standard Investigation | Transvaginal pelvic ultrasound demonstrating an antral follicle count of 20 or more per ovary and/or an increased ovarian volume greater than 10 mL in at least one ovary (utilizing equipment with a frequency of $\ge 8\text{ MHz}$)1,4. |
| Laboratory Panel | Elevated serum total testosterone, free testosterone, or free androgen index (FAI); normal or mildly elevated luteinizing hormone with a high LH/FSH ratio (often $> 2:1 or 3:1$); normal-to-low follicle-stimulating hormone levels; and elevated anti-Müllerian hormone (AMH) reflecting high antral follicle stock. |
| Imaging / Radiology (X-ray, US, CT, MRI) | Transvaginal ultrasonography showing peripheral arrangement of small antral follicles (the classic "string of pearls" sign) surrounding an enlarged, echogenic ovarian stroma. (Note: transabdominal ultrasound is preferred in adolescents, where follicle count thresholds are less reliable)3,4. |
| ECG / Histopathology / Procedural | Endometrial biopsy (via pipelle sampling) indicated in patients with prolonged, unprotected exposure to unopposed estrogen (e.g., persistent amenorrhea exceeding 3 to 6 months) to evaluate for atypical endometrial hyperplasia or carcinoma4. |
Staging, Classification & Clinical Scoring Systems
| Criterion / Stage / Score Component | Clinical Threshold, Points & Management Implication |
|---|---|
| Rotterdam Phenotype A (Classic PCOS) | Presence of all three criteria: oligo-anovulation + clinical/biochemical hyperandrogenism + polycystic ovarian morphology. Confers the highest metabolic risk profile, insulin resistance, and cardiovascular morbidity. |
| Rotterdam Phenotype B (Ovulatory PCOS) | Presence of hyperandrogenism + polycystic ovarian morphology, with normal ovulatory cycles. Often presents primarily with cutaneous manifestations or incidental ultrasound findings. |
| Rotterdam Phenotype C (Non-androgenic / Ovulatory Dysfunction + PCO) | Presence of oligo-anovulation + polycystic ovarian morphology, with normal androgen levels. Milder clinical course and lower metabolic risk. |
| Rotterdam Phenotype D (Normoandrogenic / Mild Phenotype) | Presence of oligo-anovulation + hyperandrogenism, with normal ovarian morphology on ultrasound. Represents patients with classic biochemical or clinical androgen excess and irregular menses without classical cystic morphology. |
Differential Diagnosis
| Differential Condition | Distinguishing Clinical, Biochemical & Imaging Features |
|---|---|
| Non-Classical Congenital Adrenal Hyperplasia (NCCAH) | Caused by 21-hydroxylase deficiency; distinguished by markedly elevated early-morning follicular phase 17-hydroxyprogesterone levels (basal levels $> 2.0\text{ ng/mL} or > 6\text{ nmol/L}$ requiring an ACTH stimulation test). |
| Hyperprolactinaemia | Presents with menstrual irregularity and galactorrhea; distinguished by elevated serum prolactin levels. Rule out prolactinoma via pituitary MRI if markedly elevated. |
| Thyroid Dysfunction (Hypothyroidism or Hyperthyroidism) | Can cause secondary menstrual irregularities and anovulation; distinguished by abnormal thyroid-stimulating hormone (TSH) and free thyroxine (T_4) panels. |
| Androgen-Secreting Tumours (Ovarian or Adrenal) | Characterized by rapid-onset, severe virilization (rapidly progressive hirsutism, voice deepening, clitoromegaly) and markedly elevated serum total testosterone levels (typically $> 5.5-6.0\text{ ng/mL} or > 200\text{ ng/dL}$ or dehydroepiandrosterone sulfate [DHEAS]). |
Management & Treatment Protocol
- Initial Stabilization & Resuscitation: Assess acute metabolic stability, screen for undiagnosed impaired glucose tolerance or type 2 diabetes mellitus via oral glucose tolerance testing, and evaluate cardiovascular risk factors including baseline lipid profile and blood pressure measurement1,4.
- First-Line Medical / Pharmacological Therapy (with exact adult dosing):
- Combination Oral Contraceptive Pills (COCPs): Ethinylestradiol 20 to 30 mcg combined with a progestin (such as levonorgestrel, drospirenone, or norgestimate) administered cyclically or continuously to regulate menses, protect the endometrium against hyperplasia, and suppress ovarian androgen production.
- Insulin Sensitizers: Metformin administered at an initial adult dose of 500 mg orally once daily with an evening meal, titrated gradually over 2 to 4 weeks to a therapeutic dose of 850 mg to 1000 mg orally twice daily to improve metabolic parameters, reduce hyperinsulinemia, and assist with weight management.
- Anti-androgen Therapy: Spironolactone 50 mg to 100 mg orally once or twice daily (initiated only in conjunction with reliable contraception due to teratogenic potential) for persistent hirsutism after at least 6 months of lifestyle and COCP therapy.
- Surgical / Interventional Indications: Laparoscopic ovarian drilling (LOD) reserved as a second-line therapy for women with clomiphene-resistant anovulatory infertility who fail medical ovulation induction protocols.
Complications & Prognosis
- Reproductive and Obstetric Complications: Chronic anovulation leads to primary or secondary infertility, while pregnancies complicated by polycystic ovary syndrome carry elevated relative risks for gestational diabetes mellitus, pregnancy-induced hypertension, pre-eclampsia, and preterm delivery3,4.
- Long-Term Metabolic and Oncogenic Sequelae: Persistent insulin resistance significantly accelerates the development of impaired glucose tolerance, metabolic syndrome, and early-onset type 2 diabetes mellitus. Unopposed estrogen exposure substantially increases the lifetime risk of atypical endometrial hyperplasia and endometrial carcinoma4.
- Psychological Morbidity: High prevalence rates of comorbid anxiety, depression, body image distress, and eating disorders necessitate routine psychosocial screening and integrated multidisciplinary support throughout the lifespan3,4.